Table 2 Frequency of treatment reduction of the second course and its reduction causes, severe neutropenic symptoms at the first course of DOC + RAM treatment, and RDI of DOC and RAM.
Treatment reduction of the second course (n, %) | 40 (25.8%) |
Dose reduction of DOC to 80% dosage alone | 20 (50.0%) |
Dose reduction of both medicines to 80% dosage | 10 (25.0%) |
Discontinuation of RAM alone | 8 (20.0%) |
Dose reduction of RAM alone to 80% dosage | 1 (2.5%) |
Dose reduction of DOC (80%) with RAM discontinuation | 1 (2.5%) |
Treatment reduction due to | |
Febrile neutropenia | 20 (50.0%) |
Neutropenia | 6 (15.0%) |
Bleeding | 3 (7.5%) |
Oral mucositis | 2 (5.0%) |
Fluid retention | 2 (5.0%) |
Multiple adverse effects beyond tolerability | 2 (5.0%) |
Thrombopenia | 1 (2.5%) |
Hand foot skin reaction | 1 (2.5%) |
Fatigue | 1 (2.5%) |
Decrease of performance status | 1 (2.5%) |
Hepatotoxicity | 1 (2.5%) |
Frequency of febrile neutropenia at the first course (n, %) | 26 (16.8%) |
Frequency of grade 3/4 neutropenia at the first course (n, %) | 61 (39.4%) |
Prophylactic G-CSF administration from the second course | 33 (21.3%) |
RDI at the first course (%, mean ± SD) | |
DOC | 98.8 ± 5.2 |
RAM | 99.3 ± 3.5 |
RDI at the second course (%, mean ± SD) | |
DOC | 95.7 ± 8.4 |
RAM | 91.9 ± 24.8 |
